AveXis Announces Potential Price for IPO
AveXis expects to price more than 4 million shares in the range of $19 to $21 in an initial public offering valued at up to more than $102 million.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 227
Investors OK With Pfizer Earnings, Not OK With Guidance
Pfizer reported better-than-expected fourth-quarter and full-year 2015 results before markets opened Tuesday morning.
What to Expect From Pfizer Earnings
Pfizer is scheduled to report its fourth-quarter financial results before the markets open on Tuesday.
PLx Pharma Gets Closer to IPO Debut
More than 3 million PLx Pharma shares are expected to price in the range of $17 to $19 per share in an initial public offering valued up to about $83 million.
Neos Therapeutics Gears Up for Secondary Offering
Neos Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.
Could This Be the Turning Point for TrovaGene?
Despite being a small medical laboratory and research firm, TrovaGene offered cover for investors in Monday's session from a downturn in the broad markets.
Is Alere Really Worth the 50% Premium?
Alere absolutely skyrocketed in Monday’s regular session following the announcement that it will be acquired by Abbott Laboratories.
The 4 Largest Biotech Stocks Are Cheaper Than S&P 500
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher rates of…
Exelixis Rises on Positive Late-Stage Trial Results
Exelixis shares were rising early Monday following the release of positive results from its late-stage trial of cabozantinib.
3 Key FDA Decisions Expected in February
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Despite Target Cuts, Analysts Stick With Incyte for Big Upside
After the announcement that its Phase 2 trial of Ruxolitinib would be stopped a few analysts took a deeper look at Incyte and realized that it might not be as bad as initially thought.
Investors Were Not Impressed With AbbVie Q4 Earnings
AbbVie reported mixed fourth-quarter financial results after the markets closed Thursday.
Amgen Posts Handy Beat on Estimates and Guidance
Amgen reported better-than-expected fourth-quarter financial results after the markets closed Thursday.
What to Look For in AbbVie Earnings
AbbVie is scheduled to report its fourth-quarter financial results before the markets open Friday.
Celgene Earnings, Guidance Fail to Live Up to Investor Expectations
Celgene reported mixed fourth-quarter financial results before the markets opened on Thursday.